DOCS

Doximity, Inc. (DOCS)

Healthcare • Health Information Services

StockNYSEUnited StatesUS26622P1075

33.20 USD -0.06% today Updated 13 Nov 2026 10:19

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Doximity, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 10:19. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 04 Feb 2027 in 83 days · 16:00 · estimate 0.44

Last results 0.36 vs 0.35 estimated 05 Nov 2026 · Beat +2.8%

Beat the estimate 10 of 12 2 missed · 0 in line

Average surprise +15.9% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
04 Feb 2027 16:00	0.44	—	—	Upcoming
05 Nov 2026 16:00	0.35	0.36	+2.8%	Beat
06 Aug 2026 16:00	0.30	0.29	-4.2%	Miss
13 May 2026 16:00	0.28	0.26	-7.9%	Miss
05 Feb 2026 16:00	0.45	0.46	+2.9%	Beat
06 Nov 2025 16:00	0.38	0.45	+18.7%	Beat
07 Aug 2025 16:00	0.31	0.36	+17.2%	Beat
15 May 2025 16:00	0.27	0.38	+39.3%	Beat
06 Feb 2025 16:00	0.34	0.45	+34.0%	Beat
07 Nov 2024 16:00	0.26	0.30	+17.0%	Beat
08 Aug 2024 16:00	0.23	0.28	+24.4%	Beat
16 May 2024 16:00	0.20	0.25	+24.1%	Beat
08 Feb 2024 16:00	0.24	0.29	+23.0%	Beat
09 Nov 2023 16:00	0.18	0.22	+21.1%	Beat
08 Aug 2023 16:00	0.15	0.19	+30.2%	Beat
16 May 2023 16:00	0.17	0.20	+16.0%	Beat
09 Feb 2023 16:00	0.17	0.22	+27.9%	Beat
10 Nov 2022 16:00	0.16	0.17	+7.4%	Beat
04 Aug 2022 16:00	0.11	0.14	+28.6%	Beat
17 May 2022 16:00	0.15	0.21	+41.0%	Beat
08 Feb 2022 16:00	0.12	0.29	+133.0%	Beat
09 Nov 2021 16:00	0.09	0.19	+104.6%	Beat
10 Aug 2021 16:00	0.08	0.11	+44.6%	Beat

Annual results · USD

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2026	644.9M	+13.1%	196.1M	30.4%	0.98	-11.7%	317.5M
2025	570.4M	+20.0%	223.2M	39.1%	1.11	+54.2%	266.7M
2024	475.4M	+13.5%	147.6M	31.0%	0.72	+35.8%	178.3M
2023	419.1M	—	112.8M	26.9%	0.53	—	173.4M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in USD, by day
Period	Opening price	High	Low	Closing price	Change	Volume
12 Nov 2026	32.97	33.89	32.82	33.20	-0.06%	1,950,000
11 Nov 2026	32.36	33.63	31.96	33.22	+2.47%	2,277,700
10 Nov 2026	32.49	32.79	31.87	32.42	-1.37%	2,134,700
09 Nov 2026	32.24	33.09	31.90	32.87	+1.11%	3,072,600
06 Nov 2026	30.26	32.62	29.80	32.51	-2.02%	4,293,000
05 Nov 2026	34.76	35.15	32.96	33.18	-4.30%	2,657,600
04 Nov 2026	33.10	34.92	32.92	34.67	+6.35%	3,000,000
03 Nov 2026	32.38	33.08	31.93	32.60	-0.82%	2,152,200
02 Nov 2026	32.89	33.74	32.80	32.87	+0.34%	1,773,500
30 Oct 2026	33.48	33.88	32.49	32.76	-2.59%	2,202,200
00 Mon 0000	157.29	236.48	315.67	394.86	+0.00%	000,000
00 Mon 0000	553.24	632.43	711.62	790.81	+0.00%	000,000
00 Mon 0000	49.19	128.38	207.57	286.76	+0.00%	000,000
1,251 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Doximity CEO Jeff Tangney on Putting Doctors First as AI Rewrites Healthcare (opens in a new tab) 11 Nov 2026 13:49
Doximity (DOCS) Rolls Out DoseCheck After Near Zero Drug Dosing Errors (opens in a new tab) Simply Wall St. · 10 Nov 2026 19:15
Freedom Capital Markets Maintains Hold on Doximity, Raises Price Target to $32 (opens in a new tab) Benzinga · 10 Nov 2026 08:46
Doximity: 3 Key Takeaways for Long-Term Investors (opens in a new tab) Motley Fool · 10 Nov 2026 01:11
DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression (opens in a new tab) StockStory · 09 Nov 2026 00:53
Doximity Q2 Earnings Call Highlights (opens in a new tab) MarketBeat · 07 Nov 2026 09:15
Doximity earnings analysis: questions answered and next catalysts (opens in a new tab) Investing.com · 06 Nov 2026 18:35
Doximity, Inc. (DOCS) Q2 2027 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 06 Nov 2026 17:44
Canaccord Genuity Maintains Buy on Doximity, Raises Price Target to $40 (opens in a new tab) Benzinga · 06 Nov 2026 15:47
RBC Capital Maintains Outperform on Doximity, Raises Price Target to $34 (opens in a new tab) Benzinga · 06 Nov 2026 14:18
Doximity, Inc. Q2 2027 Earnings Call Summary (opens in a new tab) Moby · 06 Nov 2026 13:30
Evercore ISI Group Maintains In-Line on Doximity, Lowers Price Target to $33 (opens in a new tab) Benzinga · 06 Nov 2026 10:44
Doximity (DOCS) Q2 2027 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 08:31
Doximity, Inc. Announces Fiscal 2027 Second Quarter Financial Results (opens in a new tab) Fintel · 06 Nov 2026 08:18
Needham Reiterates Buy on Doximity, Maintains $41 Price Target (opens in a new tab) Benzinga · 06 Nov 2026 06:31

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 33.22 USD
Market cap: 5.9B
Exchange: NYSE
Country: United States
Sector: Healthcare
Industry: Health Information Services
Currency: USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the score	Points	Why
Business growth Yearly growth of revenue and of earnings per share.	25.0 / 25	Revenue growth of 15.5% a year Earnings per share growth of 22.7% a year
Quality Return on equity, net margin and how stable the margins are.	15.8 / 25	ROE of 14%
Financial strength Net debt against operating earnings, interest cover and free cash flow.	20.0 / 20	Net debt is -3.8× EBITDA Free cash flow yield of 4.9%
Valuation Free cash flow yield and the P/E against its sector.	6.9 / 15	P/E 46.1 against 30.6 for its sector
Analysts How far the analysts' average target is from today's price.	1.3 / 10	Analysts' target is -6% from the price

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (trailing)	46.14×	Weak	30.56×
P/E (forward)	21.43×	Fair	14.16×
Price / book	6.38×	Weak	3.5×
Price / sales	8.96×	Weak	3.33×
EV / EBITDA	27.83×	Weak	11.19×
Free cash flow yield	4.9%	Fair	2.1%

Quality
Figure	Value	Reading	Sector median
Gross margin	86.8%	Good	54.9%
Operating margin	27.1%	Good	5.8%
Net margin	21.1%	Good	1.2%
Return on equity	13.8%	Fair	4.4%
Return on assets	9.5%	Good	2.7%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	15.5%	Good	10.1%
EPS growth / year	22.7%	Good	10.2%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	0.01×	Good	0.4×
Net debt / EBITDA	-3.75×	Good	1.46×
Current ratio	6.37×	Good	2.64×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	0%	Weak	0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow DOCS and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in